Sweden · Delayed Price · Currency is SEK Q-linea AB Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw strong expansion with five new ASTar instruments shipped, FDA approval for an expanded menu, and four new distribution agreements. Operating income improved significantly year-over-year due to cost reductions, and the company ended the quarter with SEK 187 million in cash.
-
Record Q1 for instrument placements and consumables demand, driven by FDA V2 menu clearance in the U.S. and steady European growth. OpEx reduced 47% year-over-year, with a strong pipeline and new product launches expected to accelerate growth.
Fiscal Year 2025
-
Revenue grew over 400% year-over-year in 2025, driven by instrument placements and consumables. U.S. growth is expected to accelerate after FDA clearance in 2026, with breakeven targeted for 2027. OpEx reductions and strong liquidity position support continued expansion.
-
Recurring income grew 370% year-over-year, driven by increased instrument activations and consumables demand, with a robust pipeline in over 15 countries. Cost reductions and a major rights issue secure liquidity, while FDA clearance for the V2 menu remains a key near-term catalyst.
-
Q2 saw five new instrument placements, strong pipeline growth, and robust cost control. Financials improved year-over-year, with a completed capital raise and clear path to break-even by 2027. Italy leads adoption, while the U.S. and other regions are progressing through early stages.
-
Record Q1 sales and five new contracts drove strong commercial momentum, with expanding U.S. and international presence. Cost control remains solid, and break-even is targeted for 2027, supported by new equity and ongoing efforts to secure non-dilutive funding.
Fiscal Year 2024
-
2024 saw the company solidify its leadership in rapid AST, achieving FDA clearance, expanding commercial activities, and executing major cost reductions. With a strong pipeline and growing market traction in the U.S. and Europe, breakeven is targeted for 2027.
-
Targeting rapid AST market growth, the company expanded its U.S. and European pipeline, completed cost restructuring, and launched a SEK 225 million rights issue to fund pivotal commercial expansion. Q3 saw improved operating results and key reimbursement wins.
-
FDA approval enabled US commercial launch and global expansion, while a cost-saving program exceeded expectations. Q2 saw low revenue due to the reagent rental model, but financing is secured and US market focus is expected to drive future growth.